< Back to search
Filter
1

Effect of Text Message Reminders on M-ISI Score After Prostate Surgery

for
Incontinence, Urinary Stress, Prostate Cancer,
Location: Rochester NY
Sponsor: University of Rochester

Sex: Male

Age: 18+

Code: NCT07071207

Recruiting

A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer

for
Advanced or Metastatic Adrenocortical Carcinoma,
Location: Providence RI, New York NY, Sarasota FL
Sponsor: Daiichi Sankyo

Sex: All

Age: 18+

Code: NCT07189403

Phase1, Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

for
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Location: Montreal, Myrtle Beach SC, Durham NC, Charleston SC,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07190300

Phase1, Phase2, Recruiting

Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)

for
Prostate Cancer
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: Male

Age: 18+

Code: NCT07210086

Phase2, Recruiting

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

for
Breast Cancer, Prostate Cancer
Location: Oklahoma City OK
Sponsor: University of Oklahoma

Sex: All

Age: 18+

Code: NCT07014618

Recruiting

Interested in new prostate cancer trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

An Evidence-Based Focal Cryotherapy Protocol for Focal Ablation of Intermediate Risk Prostate Cancer

for
Prostate Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: Male

Age: 18+

Code: NCT05454488

Phase2, Recruiting

Flotufolastat F 18 PET in Men With Very Low PSA Recurrence

for
Prostate Cancer (Adenocarcinoma), Prostate Specific Antigen
Location: Boston MA
Sponsor: Massachusetts General Hospital

Sex: Male

Age: 18+

Code: NCT06862856

Recruiting

A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate or Darolutamide

for
Prostate Cancer (Adenocarcinoma),
Location: Boston MA, New York NY, Philadelphia PA, Madison WI,
Sponsor: Prostate Cancer Clinical Trials Consortium

Sex: Male

Age: 18+

Code: NCT06844383

Phase2, Recruiting

Circulating Tumor DNA in High Risk Localized Prostate Cancer

for
Prostate Cancer
Location: Pittsburgh PA
Sponsor: University of Pittsburgh

Sex: Male

Age: 18+

Code: NCT07222436

Recruiting

Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer

for
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Location: Salt Lake City UT
Sponsor: University of Utah

Sex: Male

Age: 18+

Code: NCT07216248

Phase2, Recruiting

A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)

for
Castration-Resistant Prostatic Cancer, Metastasis
Location: Sherbrooke, New York NY, Montreal, Washington D.C. DC,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06863272

Phase1, Phase2, Recruiting

Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial

for
Castration-Sensitive Prostate Carcinoma,
Location: Stony Brook NY, Commack NY, Berlin Corners VT,
Sponsor: Alliance for Clinical Trials in Oncology

Sex: Male

Age: 18+

Code: NCT06931340

Phase3, Recruiting

Stratagen Quantitative Prostate MRI Platform Pilot Study

for
Prostate Cancer
Location: Richmond VA, Rochester NY
Sponsor: Stratagen Bio, Inc.

Sex: Male

Age: 40 - 70+

Code: NCT06985238

Recruiting

Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

for
Small Cell Lung Carcinoma,
Location: Boston MA, Montreal, Royal Oak MI, Iowa City IA,
Sponsor: Novartis Pharmaceuticals

Sex: All

Age: 18 - 70+

Code: NCT07006727

Phase1, Recruiting

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

for
Prostate Cancer (Adenocarcinoma)
Location: Philadelphia PA
Sponsor: Fox Chase Cancer Center

Sex: Male

Age: 18+

Code: NCT07219303

Recruiting

An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

for
Progressive Metastatic Castrate Resistant Prostate Cancer
Location: Halifax, Boston MA, Durham NC, Cleveland OH, Atlanta GA,
Sponsor: Novartis Pharmaceuticals

Sex: Male

Age: 18+

Code: NCT07206056

Phase1, Phase2, Recruiting

A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

for
Metastatic Castration-Resistant Prostate Cancer
Location: New Haven CT, Myrtle Beach SC, Charlottesville VA,
Sponsor: Kyntra Bio

Sex: Male

Age: 18+

Code: NCT06842498

Phase2, Recruiting

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

for
Metastatic Castration-resistant Prostate Cancer
Location: Hartford CT, Sherbrooke, New York NY, Montreal,
Sponsor: Amgen

Sex: Male

Age: 18+

Code: NCT07213674

Phase3, Recruiting

Study of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer

for
Metastatic Prostate Cancer
Location: Boston MA, Providence RI, New York NY, Myrtle Beach SC,
Sponsor: AstraZeneca

Sex: Male

Age: 18 - 70+

Code: NCT07181161

Phase1, Phase2, Recruiting

DESTINY-PANTUMOUR04

for
Adenocarcinoma (NOS), Anal Cancer, Bladder Cancer,
Location: Philadelphia PA, Wilson NC, Durham NC,
Sponsor: AstraZeneca

Sex: All

Age: 18 - 70+

Code: NCT07124000

Recruiting